MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Cagrilintide + Semaglutide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
CagriSema is the fixed-dose combination of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist), both at 2.4 mg weekly — Novo Nordisk's flagship Phase 3 combination submitted to the FDA in December 2025. The combination exploits two complementary satiety pathways: amylin and calcitonin receptor signaling in the brainstem (cagrilintide) plus hypothalamic GLP-1 receptor activation (semaglutide), producing an additive rather than redundant effect on appetite suppression. In the pivotal REDEFINE-1 trial (Garvey et al., NEJM 2025), CagriSema 2.4/2.4 mg produced 22.7% mean weight loss at 68 weeks compared to 11.8% with cagrilintide alone, 16.1% with semaglutide alone and 2.3% with placebo, with 40.4% of participants achieving at least 25% weight loss [1]. CagriSema is not yet FDA approved; the NDA review is expected to complete in 2026.
Reconstitute: Add 3 mL bacteriostatic water → 3.33 mg/mL concentration.
Typical dose: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL = 0.0333 mg (33 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days.
Regulatory status: Submitted to FDA in December 2025 for chronic weight management based on REDEFINE-1. Not yet approved by any regulator; FDA decision anticipated in 2026 [1].
Combination synergy: Cagrilintide adds 6.6 percentage points of weight loss on top of semaglutide alone in REDEFINE-1 (22.7% vs 16.1%), and 40.4% of CagriSema participants reached at least 25% weight loss vs 16.2% on semaglutide monotherapy [1].
Tolerability: CagriSema's GI side-effect profile in REDEFINE-1 was broadly similar to semaglutide alone, suggesting cagrilintide adds efficacy without proportionally adding GI burden — consistent with its non-nausea-mediated satiety mechanism.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until fully dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.
Interactive Cagrilintide + Semaglutide Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 3 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 3mL water yields 3.33 mg/mL. To evaluate a 250mcg dose, pull to 7.5 units (8 syringe ticks).
U-100 Syringe Representation
7.5 Units (8 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week/Phase | Dose per Peptide (mcg / mg) | Units (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) each | 15 units (0.15 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) each | 30 units (0.30 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) each | 60 units (0.60 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg (2.4 mg) each | 144 units (1.44 mL) |
Administration guidelines: Refer to guidelines | 3 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each):
- check8 weeks ≈ 1 vial (~6 mg total used)
- check12 weeks ≈ 2 vials (~14 mg total used)
- check16 weeks ≈ 3 vials (~27.6 mg total used)
Insulin Syringes (U‑100):
- checkPer week: 1 syringe (once weekly)
- check8 weeks: 8 syringes
- check12 weeks: 12 syringes
- check16 weeks: 16 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- check8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- check12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- check16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- checkPer week: 2 swabs
- check8 weeks: 16 swabs
- check12 weeks: 24 swabs
- check16 weeks: 32 swabs → recommend 1 × 100‑count box
Mechanism of Action (MOA)
CagriSema combines two long-acting subcutaneous peptides with non-overlapping satiety mechanisms in a single weekly injection. Semaglutide is a 31-amino-acid GLP-1 receptor agonist with a 7-day half-life, while cagrilintide is a 37-amino-acid amylin analogue with a similar terminal half-life of approximately 7–8 days [1][2]. Both are lipidated to drive albumin binding and clearance is by proteolytic degradation. The peptides are administered together via a co-formulated solution in a single fixed-dose pen device. Pharmacokinetics of each peptide in the combination are consistent with monotherapy administration; no clinically meaningful drug-drug interaction has been observed in Phase 1b co-administration studies [2]. The pharmacologic rationale is mechanistic complementarity. GLP-1 receptor activation reduces appetite via hypothalamic POMC/AgRP signaling, slows gastric emptying, and enhances glucose-dependent insulin secretion. Amylin receptor (AMY) and calcitonin receptor (CTR) activation engage a parallel satiety pathway primarily through the brainstem area postrema and other circumventricular regions — anatomically and pharmacologically distinct from the GLP-1 circuit. Phase 1b co-administration studies (Enebo et al., Lancet 2021) demonstrated that the two pathways produce additive rather than redundant weight loss [2], a finding subsequently confirmed at scale in REDEFINE-1 where the combination exceeded both monotherapies by clinically meaningful margins [1]. The combination also produces synergistic effects on gastric emptying and glycemic control, supporting the broader cardiometabolic profile. Administration is subcutaneous via fixed-dose pen device into the abdomen, thigh or upper arm. Steady-state pharmacokinetics are reached after about 5 weeks of weekly dosing. The titration protocol used in REDEFINE-1 escalates both peptides in parallel every 4 weeks: 0.25/0.25 → 0.5/0.5 → 1.0/1.0 → 1.7/1.7 → 2.4/2.4 mg over a 16-week ramp. Earlier Phase 2 dose-finding work explored an even slower 20-week ramp. Maintenance dosing is the fixed 2.4/2.4 mg per injection. Downstream effects beyond weight loss are extensive: in REDEFINE-1, CagriSema produced placebo-adjusted reductions in systolic blood pressure (~8 mmHg), triglycerides (~30%), HbA1c (~0.4% greater than semaglutide alone), and waist circumference (~13 cm). Body-composition substudies showed approximately 70% of weight lost was fat mass with reasonable preservation of lean mass [1]. A separate Phase 2 T2D trial established the metabolic profile in patients with type 2 diabetes [3]. The REDEFINE-2 Phase 3 trial in patients with T2D is in progress and will define the broader metabolic indication.
Clinical Trial Efficacy Highlights
- starREDEFINE-1 (Novo Nordisk, 2024–2025) is the pivotal Phase 3 randomized trial of CagriSema 2.4/2.4 mg weekly in 3,417 adults with overweight or obesity without diabetes. At 68 weeks, mean body-weight reduction was 22.7% on CagriSema vs 11.8% with cagrilintide 2.4 mg alone, 16.1% with semaglutide 2.4 mg alone, and 2.3% with placebo [1].
- starIn REDEFINE-1, 40.4% of CagriSema participants achieved ≥25% weight loss compared to 6.0%, 16.2% and 0.9% in the cagrilintide-only, semaglutide-only and placebo arms respectively — the highest ≥25% loss rate ever reported for an approved-class combination [1].
- starPhase 1b combination trial (Enebo et al., Lancet 2021) of cagrilintide + semaglutide co-administration over 20 weeks showed mean weight loss of 17.1%, substantially greater than the additive effect predicted from monotherapy data alone — establishing the mechanistic synergy hypothesis [2].
- starREDEFINE-2 (in progress) is the Phase 3 trial of CagriSema in patients with overweight/obesity AND type 2 diabetes; topline data are expected to read out in 2025–2026.
- starPhase 2 T2D trial (Frias et al., Lancet 2023) comparing CagriSema to semaglutide 2.4 mg alone in adults with T2D demonstrated CagriSema produced an additional 2.4% weight loss and 0.4% greater HbA1c reduction at 32 weeks, establishing additive benefit in the diabetic population [3].
- starBody-composition substudies in REDEFINE-1 using DXA showed approximately 70% of weight lost on CagriSema was fat mass, with visceral-adipose-tissue reductions exceeding 35% and modest lean-mass loss in line with other incretin trials [1].
- starCardiometabolic secondary endpoints in REDEFINE-1 included systolic blood pressure reductions of approximately 8 mmHg, triglyceride reductions of approximately 30%, and waist-circumference reductions of approximately 13 cm — broadly stronger than for either monotherapy.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal events in REDEFINE-1 occurred at rates broadly similar to semaglutide monotherapy: nausea approximately 45%, diarrhea 30%, vomiting 25% and constipation 22% on CagriSema vs 16%, 18%, 8% and 12% on placebo. Most were mild-to-moderate and concentrated during titration [1].
- warningImportantly, the additive efficacy of CagriSema does not appear to come at the cost of proportionally additive GI burden — discontinuation rates for GI events were approximately 6% on CagriSema vs 4% on semaglutide alone, suggesting the amylin component adds efficacy without substantially worsening tolerability [1].
- warningHeart-rate elevation of 3–5 beats per minute on average was observed, broadly consistent with semaglutide monotherapy. The minimal chronotropic effect of cagrilintide does not appear to add to this signal.
- warningCholelithiasis and acute cholecystitis occurred at rates broadly consistent with semaglutide alone — likely driven by the rapid weight-loss component rather than direct gallbladder effects of either peptide.
- warningFDA labeling for the eventual CagriSema approval will likely carry the semaglutide boxed warning for medullary thyroid carcinoma risk based on rodent C-cell carcinogenicity data, contraindicating use in patients with personal or family history of MTC or MEN-2.
- warningAcute pancreatitis was rare in REDEFINE-1 (<0.5%), consistent with the semaglutide class effect. Patients with prior pancreatitis history should use cautiously.
- warningInjection-site reactions occurred in approximately 4–6% of participants, generally mild and self-limited. The co-formulated pen device delivers both peptides in a single injection volume.
- warningHypoglycemia is uncommon in non-diabetic participants; in diabetic populations using CagriSema with insulin or sulfonylureas, background therapy adjustment is required.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical CagriSema dosage?expand_more
CagriSema is dosed once weekly subcutaneously as a fixed 2.4 mg cagrilintide + 2.4 mg semaglutide combination. Standard titration ramps both peptides in parallel every 4 weeks: 0.25/0.25 → 0.5/0.5 → 1.0/1.0 → 1.7/1.7 → 2.4/2.4 mg, reaching maintenance at week 16. The combined dose is delivered as a single subcutaneous injection via fixed-dose pen device.
How is CagriSema different from Semaglutide alone?expand_more
CagriSema combines semaglutide (GLP-1 agonist) with cagrilintide (amylin analogue) — two different satiety pathways. In REDEFINE-1, CagriSema produced 22.7% weight loss vs 16.1% with semaglutide alone at 68 weeks — a 41% relative improvement. The two mechanisms are anatomically and pharmacologically distinct, allowing additive effects without proportionally additive side effects [1].
What are the most common side effects of CagriSema?expand_more
Most common are GI: nausea (~45%), diarrhea (~30%), vomiting (~25%), constipation (~22%) — broadly comparable to semaglutide monotherapy. Other notable: gallbladder events, mild heart-rate increase, small risk of acute pancreatitis. The label will likely carry semaglutide's MTC boxed warning. Discontinuation rate is ~6% [1].
How should CagriSema be reconstituted and stored?expand_more
The commercial CagriSema (when approved) will be supplied as a pre-filled fixed-dose pen — no reconstitution required. Store at 2–8 C, protect from light, and may be kept at room temperature (up to 30 C) for up to 28 days once in use. Do not freeze. If compounded as separate vials, store reconstituted solutions refrigerated and use within 28 days.
Is CagriSema FDA approved?expand_more
Not yet. The Novo Nordisk NDA was submitted to FDA in December 2025 based on REDEFINE-1 Phase 3 data, with anticipated approval decision in 2026. CagriSema would be the first once-weekly fixed-dose combination of a GLP-1 and amylin analogue for chronic weight management. Until approval, the combination remains investigational [1].
Academic References & Study Citations
Garvey WT, Blüher M, Osorto Contreras CK, et al. (2025) N Engl J Med. 'Cagrilintide–Semaglutide in Adults with Overweight or Obesity' (REDEFINE-1). 22.7% weight loss at 68 weeks. View Scientific Paper →
Enebo LB, Berthelsen KK, Kankam M, et al. (2021) Lancet 397:1736-1748. 'Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial'. View Scientific Paper →
Frias JP, Deenadayalan S, Erichsen L, et al. (2023) Lancet 402:720-730. 'Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial'. View Scientific Paper →
Lau DCW, Erichsen L, Francisco AM, et al. (2021) Lancet 398:2160-2172. 'Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial'. View Scientific Paper →
Wilding JPH, Batterham RL, Calanna S, et al. (2021) N Engl J Med 384:989-1002. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity' (STEP-1). 14.9% weight loss at 68 weeks on 2.4 mg. View Scientific Paper →
Hay DL, Chen S, Lutz TA, et al. (2015) Pharmacol Rev. 'Amylin: pharmacology, physiology, and clinical potential' — comprehensive amylin biology review. View Scientific Paper →
ClinicalTrials.gov NCT05567796 — REDEFINE-1 Phase 3 CagriSema obesity trial registration. View Scientific Paper →
ClinicalTrials.gov NCT05669519 — REDEFINE-2 Phase 3 CagriSema in obesity plus T2D trial. View Scientific Paper →
Novo Nordisk press release (December 2025) — FDA NDA submission for CagriSema in chronic weight management. View Scientific Paper →